Publications

Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations

 

CTD²
April 01, 2013
Genome Research

Analytic Technique for Assessment of RNAi by Similarity (ATARiS) takes advantage of patterns in RNAi data across multiple samples in order to enrich for RNAi reagents whose phenotypic effects relate to suppression of their intended targets.

CTD²
March 01, 2013
Nature Cell Biology

Researchers show that basal- and luminal-derived prostate tumors have distinct molecular signatures.

TARGET
March 01, 2013
Nature Genetics

TARGET investigators used whole-exome, genome and transcriptome sequencing to determine the spectrum of somatic mutation in high-risk neuroblastoma.

CTD²
February 28, 2013
Cell

Researchers introduce how CRISPR interference (CRISPRi) can efficiently repress expression of targeted genes in Escherichia coli, with no detectable off-target effects, and can be used to repress multiple target genes simultaneously.

CTD²
February 19, 2013
BMC Genomics

Researchers describe a novel method to discern molecular interactions specific to certain molecular contexts.

CTD²
February 14, 2013
Cell

The authors use ultracomplex pooled shRNA libraries (25 shRNAs/gene) to identify high-confidence hit genes for a given phenotype and effective shRNAs and construct double-shRNA libraries from these to systematically measure genetic interactions between hits.

TARGET
January 17, 2013
Blood

Sequencing the tyrosine kinome and downstream signaling genes in high-risk pediatric ALL cases showed no somatic mutations aside from JAK mutations and 1 FLT3 mutation.

CTD²
December 21, 2012
Cell

Wnt/β-catenin signaling plays a key role in the pathogenesis of colon and other cancers; emerging evidence indicates that oncogenic β-catenin regulates several biological processes essential for cancer initiation and progression.

TARGET
December 08, 2012
Hematology

The study reported that alterations of the lymphoid transcription factor gene IKZF1 (IKAROS) are associated with a high risk of treatment failure in B-ALL and approximately 20% of B-ALL cases have genetic alterations that activate kinase signaling.

Pages

CSVXML